RECRUITING Not applicable ClinicalTrials.gov

Efficacy and Safety of the ELIOS Laser in Combined Cataract and Glaucoma Surgery

Sponsor: Hôpital Privé de la Baie • ClinicalTrials.gov ID: NCT06760169

Registry updated: 2026-09-30

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

Glaucoma is an irreversible optic neuropathy. It is the second most common cause of blindness worldwide. Glaucoma can be treated with topical medications (eye drops), laser or surgery. Traditional surgery is invasive and has a high complication rate (hypotonia, endophthalmitis, cataracts, etc.). As a result, several types of micro-invasive surgery (MIGS) have been developed to reduce the risks of surgery while maintaining their effectiveness in lowering intraocular pressure (IOP). The ELIOS laser system is the only ophthalmological excimer laser designed for the surgical treatment of glaucoma. The aim of the procedure is to ablate the trabecular meshwork and inner wall of Schlemm´s canal ab interno, with the creation of 10 microchannels of 210 um in the trabeculum using the ELIOS laser with a wavelength of 308 nm, in order to improve trabecular outflow to achieve a reduction in IOP. The ELIOS laser is an example of Microinvasive Glaucoma surgery (MIGS) with published results demonstrating efficacy and safety. The ELIOS laser is already in use in France (AMM / CE mark achieved). Its use as part of a prospective interventional study will enable us to collect data in order to treat patients more effectively and improve the quality of care provided to glaucoma patients.

Interventions

Surgery with ELIOS laser (Device)
This surgery involves visualizing the iridocorneal angle before or after cataract surgery, inserting the ELIOS laser probe into the anterior chamber to come into slight contact with the trabecular meshwork, then pressing the foot pedal, the surgeon activates the laser, which creates a microchannel by photoablating the trabecular meshwork and inner wall of Schlemm´s canal (trabeculostomy) ± 210 um in diameter. This gesture is repeated until 10 microchannels are created. The creation of these microchannels enhances the natural outflow of aqueous humor by bypassing the site of major resistance in the system. The usual duration of the ELIOS procedure is typically few minutes). The rest of the surgery does not deviate from standard phacoemulsification.

Eligibility criteria

Inclusion Criteria: * Patients ≥ 18 years of age who agree to take part in the study and have signed an informed consent form * Visually significant cataract with indication for surgery * Primary open-angle glaucoma, or secondary open-angle glaucoma (pseudoexfoliative glaucoma or pigmentary glaucoma) with indication for cataract surgery. * Open iridocorneal angle (Shaffer classification grade 2-4) * Early to moderate glaucoma (advanced glaucoma, with MD from VFs worse than -12dB, will be excluded) Exclusion Criteria: * Presence of severe systemic pathologies 2024-A01891-46\_Protocol\_V6\_21112024\_Elios Page 20 / 58 * Pregnant or breastfeeding women * \<18 years of age * Presence of other ophthalmological pathologies (except cataracts), and exclusion of severe dry eye. * History of intraocular surgery, trauma, or conjunctival scarring in the quadrant intended for surgery * Visual acuity worse than "counting fingers". * Closure of the iridocorneal angle (and angle-closure glaucoma), angle-closure glaucoma secondary to iridocorneal synechiae, neovascular glaucoma or neovascularization of the iris. * Normal-pressure glaucoma * Pachymetry \< 490 um or \> 620 μm * Glaucomatous visual field with mean deviation worse than ≤-12 dB * IOP \> 35 mmHg * Autoimmune disorder, especially collagenosis * Patient under protective supervision * Patient not covered by a social security scheme

Conditions

Glaucoma

Locations

Hôpital Privé de la Baie — Avranches, France

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment